Nanthealth LLC (NYSE:NH) shares fell 8.9% during trading on Tuesday . The stock traded as low as $11.28 and last traded at $11.43, with a volume of 105,739 shares traded. The stock had previously closed at $12.55.

Several brokerages have recently commented on NH. Jefferies Group began coverage on shares of Nanthealth in a report on Monday, June 27th. They set a “buy” rating on the stock. Canaccord Genuity began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set a “buy” rating and a $17.00 price target on the stock. First Analysis began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “overweight” rating and a $18.00 price target on the stock. Cowen and Company began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, FBR & Co began coverage on shares of Nanthealth in a research report on Monday, June 27th. They set an “outperform” rating and a $18.00 price target on the stock. Five analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $18.00.

The firm’s 50 day moving average price is $13.56 and its 200 day moving average price is $13.56. The company’s market cap is $6.37 billion.

In other Nanthealth news, major shareholder Healthcare Solution Allscripts purchased 714,286 shares of the stock in a transaction dated Tuesday, June 7th. The shares were bought at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the completion of the transaction, the insider now directly owns 15,000,000 shares in the company, valued at approximately $210,000,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Patrick Soon-Shiong purchased 357,143 shares of the stock in a transaction dated Tuesday, June 7th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $5,000,002.00. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.